Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nodular Basal Cell Carcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Nodular Basal Cell Carcinoma. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-000141-39 Sponsor Protocol Number: 110118 Start Date*: 2018-03-08
    Sponsor Name:Merete Hædersdal
    Full Title: Tolerabililty of laser-assisted cisplatin+5-fluorouracil― an exploratory proof of concept study of topical combination chemotherapy for basal cell carcinoma
    Medical condition: Patients over 18 years of age with a previously untreated superficial or nodular basal cell carcinoma (BCC) on the scalp, face, extremities or trunk
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-019856-30 Sponsor Protocol Number: CLDE225B2307 Start Date*: 2010-06-29
    Sponsor Name:NOVARTIS FARMA
    Full Title: A randomized, double-blind, vehicle-controlled, multicenter trial of topically administered LDE225 cream [0.75% bid] to evaluate clearance of Basal Cell Carcinoma in adult patients with Nevoid B...
    Medical condition: Basal Cell Carcinoma in adult patients with Nevoid Basal Cell Carcinoma Syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10004146 Basal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002845-40 Sponsor Protocol Number: SP848-nBCC-1104 Start Date*: 2012-11-15
    Sponsor Name:Spirig Pharma AG
    Full Title: Bi-center, open label, non-comparative trial exploring efficacy and safety of topical resiquimod gel (0.06%) in patients with nodular basal cell carcinoma (nBCC).
    Medical condition: Nodular Basal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002605-62 Sponsor Protocol Number: BCC1801 Start Date*: 2018-10-23
    Sponsor Name:Herlev and Gentofte Hospital
    Full Title: Phase IIa trial with PD-L1 IO103 vaccination with montanide in patients with basal cell carcinoma.
    Medical condition: basal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007286 Carcinoma basal cell LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002508-16 Sponsor Protocol Number: 53897 Start Date*: 2016-08-31
    Sponsor Name:Department of Dermatology D92, Bispebjerg Hospital
    Full Title: Optimized photodynamic therapy for basal cell carcinoma
    Medical condition: Basal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002545-38 Sponsor Protocol Number: 68943 Start Date*: 2019-09-13
    Sponsor Name:Bispebjerg Hospital, Department of Dermatology
    Full Title: Biodistribution of ablative fractional laser-assisted topical delivery of Vismodegib in basal cell carcinomas.
    Medical condition: Basal cell carcinoma Simple nodular basal cell carcinoma at any body locations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066495 Basal cell carcinoma recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073093 Nodular basal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-002843-14 Sponsor Protocol Number: 0407 Start Date*: 2017-09-26
    Sponsor Name:Bispebjerg Hospital
    Full Title: Investigations of local skin reactions and safety after combined treatment of basal cell carcinoma using ablative fractional laser and ingenol mebutate - an exloratory, prospective, open-label phas...
    Medical condition: Safety and local skin reactions in patients with basal cell carcinoma after combined treatment of blative fractional laser and ingenol mebutate.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-001961-14 Sponsor Protocol Number: WN07DE002 Start Date*: 2007-06-28
    Sponsor Name:Greater Glasgow and Clyde [...]
    1. Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: A pilot study of the treatment of facial nodular and nodulocystic basal cell carcinoma with double curettage and cautery followed by application of imiquimod to the base.
    Medical condition: Basal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004146 Basal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003336-72 Sponsor Protocol Number: 81413F Start Date*: 2013-10-30
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLGIA
    Full Title: A Phase IIb study of topic DAC-0060, a synthetic histone deacetylase inhibitor, plus Tazarotene in patients with cutaneous basal cell carcinoma (BCC)
    Medical condition: BASAL CELL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005769-12 Sponsor Protocol Number: RD.03.SPR.29051 Start Date*: 2006-06-12
    Sponsor Name:Galderma R&D
    Full Title: FLUORESCENT DETECTION WITH METHYL AMINOLEVULINATE OF BASAL CELL CARCINOMA: TO ASSESS THE ACCURACY OF THIS TECHNIQUE BY COMPARISON WITH RESECTION MARGIN LEFT BY MOH’S MICROGRAPHIC SURGERY AFTER DIF...
    Medical condition: Basal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10004146 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004543-40 Sponsor Protocol Number: ONC-2015-001/ML29968 Start Date*: 2016-09-20
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: A SINGLE ARM, PHASE II, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF VISMODEGIB AND RADIOTHERAPY IN PATIENTS WITH HIGH RISK OR LOCALLY ADVANCED BASAL CELL CARCINOMA NOT AMENABLE TO RADICA...
    Medical condition: HIGH RISK OR LOCALLY ADVANCED BASAL CELL CARCINOMA NOT AMENABLE TO RADICAL SURGERY
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002730-36 Sponsor Protocol Number: CaEP68962 Start Date*: 2019-11-14
    Sponsor Name:Department of Dermatology, Bispebjerg Hospital
    Full Title: Calcium electroporation for basal cell carcinomas – a ’Proof of concept’ study
    Medical condition: Basal cell carcinomas
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10042503 Superficial basal cell carcinoma LLT
    21.1 100000004864 10073093 Nodular basal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-003479-52 Sponsor Protocol Number: NL50433.068.14 Start Date*: 2014-11-10
    Sponsor Name:Maastricht University Medical Centre
    Full Title: Surgical excision versus combined therapy with Curettage and Imiquimod for the treatment of Nodular Basal Cell Carcinoma: an open, non-inferiority, randomized controlled trial
    Medical condition: Histologically proven primary nodular basal cell carcinoma ≥ 4mm and ≤ 20mm in diameter outside the face and hairy scalp.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10073093 Nodular basal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003241-42 Sponsor Protocol Number: ALA-BCC-CT008 Start Date*: 2013-12-23
    Sponsor Name:Biofrontera Bioscience GmbH
    Full Title: A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) in comparison to Metvix® in the treatment of non-aggressive basal cell carcin...
    Medical condition: Basal cell carcinoma (BCC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022410-11 Sponsor Protocol Number: 33606.068.10 Start Date*: 2011-07-18
    Sponsor Name:MUMC
    Full Title: Topical Diclofenac and Vitamin D3 to treat Basal Cell Carcinoma
    Medical condition: Basal Cell Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002856-26 Sponsor Protocol Number: ADO-EP02(ML29328) Start Date*: 2016-12-19
    Sponsor Name:SRH Wald-Klinikum Gera GmbH
    Full Title: A PHASE II, SINGLE-ARMED, MULTICENTER TRIAL OF NEOADJUVANT VISMODEGIB IN PATIENTS WITH LARGE AND/OR RECURRENT RESECTABLE BASAL CELL CARCINOMA
    Medical condition: Patients with large and/or recurrent resectable basal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000063-10 Sponsor Protocol Number: RD.03.SPR.29040 Start Date*: 2004-10-07
    Sponsor Name:Galderma R&D
    Full Title: A comparison of Metvix PDT with simple excision surgery in subjects with superficial Basal cell Carcinoma (sBCC)
    Medical condition: Superficial Basal Cell Carcinomas, occurring mostly on trunk and extremities (‎4,‎5), are progressively spreading, slow growing cancers. They can be difficult to diagnose and often mistaken for oth...
    Disease: Version SOC Term Classification Code Term Level
    10042503 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013665-26 Sponsor Protocol Number: CLDE225B2204 Start Date*: 2010-01-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study to evaluate the efficacy, safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administr...
    Medical condition: sporadic superficial skin basal cell carcinomas
    Disease: Version SOC Term Classification Code Term Level
    12.0 10042503 Superficial basal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004608-22 Sponsor Protocol Number: 17-PP-21 Start Date*: 2018-05-22
    Sponsor Name:CHU de Nice
    Full Title: Open, prospective, single-center study evaluating the efficacy and safety of 0.05% ingénol mebutate (Picato® 500) in the treatment of basal cell carcinoma Study "PICABAS"
    Medical condition: Patients with one or more basal cell carcinoma superficial, or nodular, trunk or limb
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007284 Carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002765-37 Sponsor Protocol Number: 20051 Start Date*: 2006-08-15
    Sponsor Name:Euopean Organisation of Research and Treatment of Cancer
    Full Title: The H10 EORTC/GELA randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's...
    Medical condition: Hodgkin’s lymphoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DK (Completed) FR (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA